【Invitation】CPHI China 2024 | Haibu Pharmaceutical invites you to meet in Shanghai - June 19-21
Classification:
Recent Events
Release time:
2024-06-12
Chemical Drug CRO Services
Registration and Commercial Supply Related to APIs
Customs and Commercial Supply of Advanced Pharmaceutical Intermediates
Research and Cooperation on New Coupling Drug Technologies
MAH Formulation R&D and Licensing
Import and Export of Drugs/Technologies
Beijing Haibu Pharmaceutical Technology Co., Ltd. (referred to as 'Haibu Pharmaceutical') was established in 2005 as a high-tech enterprise with 'chemical drug R&D' as its core capability. It has a Beijing R&D center, an API and formulation pilot verification center, a GMP industrial production base, mainly engaged in CRO services for APIs and formulations, MAH joint licensing, API-related declarations, as well as commercial supply of pharmaceutical intermediates.It has rich experience in R&D transfer production, registration declaration of various dosage forms such as chemical APIs, oral solids, liquid formulations, sterile injections, external preparations etc. The R&D products cover multiple therapeutic areas including anti-tumor, anti-depression, anti-epilepsy, anti-anxiety, cardiovascular diseases, digestive system diseases, respiratory system diseases etc.
Haibu Pharmaceutical has been awarded the title of 'Top 20 Chinese Pharmaceutical R&D Companies' for several consecutive years and recognized as a 'Specialized & Innovative Enterprise' by Beijing Municipality; a 'National High-tech Enterprise'; a 'Beijing Science & Technology Research Development Institution'; a 'Beijing Yizhuang Enterprise Innovation Center', among others.



